相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis
E. L. Simpson et al.
BONE (2020)
Design of a randomized trial of teriparatide followed by alendronate: Japanese Osteoporosis Intervention Trial-05 (JOINT-05)
Shiro Tanaka et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2020)
Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline
Richard Eastell et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial
David L. Kendler et al.
LANCET (2018)
Administration frequency as well as dosage of PTH are associated with development of cortical porosity in ovariectomized rats
Aya Takakura et al.
BONE RESEARCH (2017)
Acute development of cortical porosity and endosteal naive bone formation from the daily but not weekly short-term administration of PTH in rabbit
Hiroshi Yamane et al.
PLOS ONE (2017)
24-Month Open-Label Teriparatide Once-Weekly Efficacy Research Trial Examining Bone Mineral Density in Subjects with Primary Osteoporosis and High Fracture Risk
Toshitsugu Sugimoto et al.
ADVANCES IN THERAPY (2017)
Increased cortical porosity is associated with daily, not weekly, administration of equivalent doses of teriparatide
Roger Zebaze et al.
BONE (2017)
Frequency of Teriparatide Administration Affects the Histological Pattern of Bone Formation in Young Adult Male Mice
Tomomaya Yamamoto et al.
ENDOCRINOLOGY (2016)
Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial
Toshitsugu Sugimoto et al.
CURRENT MEDICAL RESEARCH AND OPINION (2013)
Diagnostic criteria for primary osteoporosis: year 2012 revision
Satoshi Soen et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2013)
Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women
M. Shiraki et al.
OSTEOPOROSIS INTERNATIONAL (2013)
Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture Risk
Toshitaka Nakamura et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Comparative Effectiveness of Drug Treatments to Prevent Fragility Fractures: A Systematic Review and Network Meta-Analysis
Mohammad Hassan Murad et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Sequential Treatment of Severe Postmenopausal Osteoporosis After Teriparatide: Final Results of the Randomized, Controlled European Study of Forsteo (EUROFORS)
Richard Eastell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis
S. Adami et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Mechanisms of anabolic therapies for osteoporosis
Ernesto Canalis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis
Peiqi Chen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis
DM Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis
JR Zanchetta et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Summary of meta-analyses of therapies for postmenopausal osteoporosis
A Cranney et al.
ENDOCRINE REVIEWS (2002)
分享论文
